Literature DB >> 400717

Normal pregnancies after treatment of hyperprolactinemia with bromoergocryptine, despite suspected pituitary tumors.

R Mornex, J Orgiazzi, B Hugues, J C Gagnaire, B Claustrat.   

Abstract

Bromocryptine treatment was administered to 15 patients with amenorrhea and galactorrhea (AG) and to 1 patient with amenorrhea. All of them had increased plasma PRL levels. Of these 16 patients, 4 had a normal sella turcica (ST; group STO), 4 had a slight enlargement (group ST+), and 7 had a clear enlargement of ST (ST++) but no evidence of suprasellar extension. Ovulation was restored in 15 patients by bromocryptine treatment only. In one patient, ovulation resumed only after human pituitary gonadotropin treatment in combination with bromocryptine. There was no correlation between basal prolactinemia, PRL stimulability or suppressibility, the size of ST, or the efficiency of bromocryptine treatment. Every patient with normal LH response to either LRH or clomiphene or both resumed ovulation. Ovulation resumed in 3 patients among the 4 with abnormal LH response to either LRH or clomiphene or both. Among the 14 who desired pregnancy, 13 became pregnant. To date, 12 patients (ST++, 5; ST+, 3; STO, 4) have delivered normal babies. The courses of pregnancy were normal. During pregnancy, no change of ST was noted on lateral and frontal skull x-ray performed in every patient at trimonthly intervals. There was no change in the sellar index in 10 patients after pregnancy, as compared to the pretreatment status. In the presence of a pituitary adenoma or in patients with hyperprolactinemia and amenorrhea and galactorrhea, bromocryptine treatment may cure sterility without pituitary complication during pregnancy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 400717     DOI: 10.1210/jcem-47-2-290

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Management of endocrine disorders in pregnancy. Part II. Pituitary, ovarian and adrenal disease.

Authors:  Z M van der Spuy; H S Jacobs
Journal:  Postgrad Med J       Date:  1984-05       Impact factor: 2.401

2.  Somatotropin secretion in hyperprolactinemia.

Authors:  B V Gorgoshidze; M A Sabakhtarashvili; E G Veinberg; R B Kurashvili; M G Dundua
Journal:  Neurosci Behav Physiol       Date:  1983 Mar-Apr

3.  Partial remission of hyperprolactinemic amenorrhea after bromocriptine-induced pregnancy.

Authors:  C Campagnoli; L Belforte; F Massara; C Peris; G M Molinatti
Journal:  J Endocrinol Invest       Date:  1981 Jan-Mar       Impact factor: 4.256

Review 4.  Use of bromocriptine in hyperprolactinaemic anovulation and related disorders.

Authors:  S Franks
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

5.  CT follow-up of microprolactinomas during bromocriptine-induced pregnancy.

Authors:  J L Dietemann; C Portha; F Cattin; E Mollet; J F Bonneville
Journal:  Neuroradiology       Date:  1983       Impact factor: 2.804

Review 6.  Treatment of hyperprolactinemia: a systematic review and meta-analysis.

Authors:  Amy T Wang; Rebecca J Mullan; Melanie A Lane; Ahmad Hazem; Chaithra Prasad; Nicola W Gathaiya; M Mercè Fernández-Balsells; Amy Bagatto; Fernando Coto-Yglesias; Jantey Carey; Tarig A Elraiyah; Patricia J Erwin; Gunjan Y Gandhi; Victor M Montori; Mohammad Hassan Murad
Journal:  Syst Rev       Date:  2012-07-24

7.  Hyperprolactinaemia--investigation and results of treatment.

Authors:  J D Wilson; D D Boyle; J M Harley; D A Montgomery; B Sheridan
Journal:  Ulster Med J       Date:  1980

8.  A Reassessment of the Therapeutic Potential of a Dopamine Receptor 2 Agonist (D2-AG) in Endometriosis by Comparison against a Standardized Antiangiogenic Treatment.

Authors:  Miguel Á Tejada; Ana I Santos-Llamas; María José Fernández-Ramírez; Juan J Tarín; Antonio Cano; Raúl Gómez
Journal:  Biomedicines       Date:  2021-03-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.